A Game-Changer in Disease Prevention: Valneva’s Single-Dose Chikungunya Vaccine, IXCHIQ®, Receives Marketing Authorization in Brazil
Valneva’s Groundbreaking Achievement
April 14, 2025 – Saint Herblain, France – In an unprecedented move, Valneva SE, a leading specialty vaccine company listed on Nasdaq and Euronext Paris under the symbols VALN and VLA, respectively, has announced that the Brazilian Health Regulatory Agency (ANVISA) has granted marketing authorization for its single-dose vaccine, IXCHIQ®, designed to prevent diseases caused by the chikungunya virus. This marks the world’s first approval of a chikungunya vaccine in an endemic country.
The Significance of the ANVISA Decision
The ANVISA decision is a pivotal moment in the fight against chikungunya, a mosquito-borne viral disease known for its debilitating symptoms, including severe joint pain, muscle pain, headache, and fever. This approval is the result of Valneva’s strategic focus on addressing health challenges in endemic countries, a collaborative effort supported by the Coalition for Epidemic Preparedness Innovations (CEPI) and the European Union (EU), and partnership with Instituto Butantan.
Collaborative Efforts to Broaden Access
CEPI, an innovative partnership between public, private, and philanthropic organizations, plays a crucial role in financing and coordinating the development of vaccines against epidemic threats. The European Union, a significant contributor to CEPI, has also shown its commitment to this cause. Valneva’s partnership with Instituto Butantan, a leading biomedical research institution in Brazil, further strengthens the efforts to make the chikungunya vaccine accessible to a broader population, particularly in low-and-middle-income countries.
The Impact on You: Enhanced Protection Against Chikungunya
For individuals living in or traveling to areas with high chikungunya virus transmission, this approval signifies a significant leap forward in disease prevention. The availability of a licensed vaccine in endemic countries will enable easier access to the vaccine, offering greater protection against this debilitating disease. Stay informed about the vaccine’s availability and accessibility in your region to ensure optimal health and wellbeing.
The Global Implications: A Safer World
The approval of IXCHIQ® in Brazil sets an important precedent for other endemic countries and the global community. The successful collaboration between Valneva, CEPI, the EU, and Instituto Butantan demonstrates the power of public-private partnerships in addressing health challenges and providing access to life-saving vaccines. This achievement not only contributes to the fight against chikungunya but also paves the way for the development and implementation of vaccines against other epidemic threats.
A Brighter Future: Continued Innovation and Collaboration
Valneva’s groundbreaking achievement in Brazil is a testament to the importance of continued innovation and collaboration in the global health landscape. As we move forward, it is crucial to maintain the momentum and build on this success to ensure that effective vaccines are available to protect individuals and communities against a range of epidemic threats. Stay informed and engaged in the ongoing efforts to improve global health and wellbeing.
- Valneva SE announces first approval of chikungunya vaccine in an endemic country (Brazil)
- ANVISA grants marketing authorization to single-dose vaccine, IXCHIQ®
- Collaborative effort supported by CEPI, EU, and Instituto Butantan
- Significant leap forward in disease prevention, particularly for individuals in endemic regions
- Sets precedent for other endemic countries and global health initiatives
As we celebrate this achievement, let us also remember that the fight against epidemic threats is an ongoing effort. Stay informed, stay engaged, and join the global community in its commitment to improving health and wellbeing for all.
